1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation

Melatonin Dose Study, Steroid Warning Show Both Sides Of Coin For US Supplement Industry Image

Latest Public Perception Peril Prompted By JAMA Research Letter, FDA SARMs Consumer Alert

 
• By Malcolm Spicer

Separate criticisms show opposite sides of the coin of public perception constantly flipping for businesses large and small making and marketing supplements available in US.

• Source: Shutterstock

The quality of a popular dietary ingredient sleep aid is doubted by researchers in one of the latest criticisms faced by the US dietary supplement industry. In another recent shadow cast across the industry, regulators renew warnings about supplements made with chemical substances which mimic the effects of testosterone and anabolic steroids.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Loper Bright Could Trip FDA On Self-Affirmed GRAS

 
• By Malcolm Spicer

Instead of arguing FDA’s not authorized to offer option under authority from 1958 Food Additives Amendments, potential litigation could contend the law requires agency to continue making self-GRAS without notification available.

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By David Ridley

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

Momentum Of Questions About Self-GRAS Meets Wall Of Exemption From ‘Rigorous Review’

 
• By Malcolm Spicer

HHS Secretary Kennedy ‘s opposition to allowing GRAS without notifications has support but also questions just as strong about whether FDA is authorized to conduct a rulemaking to eliminate the option.